Endothelial cells co-cultured with wild-type and dominant/negative p53-transfected glioblastoma cells exhibit differential sensitivity to radiation-induced apoptosis

International Journal of Cancer

Volumn 109, Issue 2, 2004, Pages 214-219

  Khodarev, Nikolai N ^a   Labay, Edwardine ^a   Darga, Thomas ^a   Yu, Jianqing ^b   Mauceri, Helena ^a   Gupta, Nalin ^c   Kataoka, Yasushi ^a   Weichselbaum, Ralph R ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Co culture; Endothelial cells; Glioblastoma; p53; Radioresistance

Indexed keywords

PROTEIN P53;

APOPTOSIS; ARTICLE; BRAIN TUMOR; CANCER CELL CULTURE; CELL CULTURE; CELL MOTION; COCULTURE; CONTROLLED STUDY; DNA MICROARRAY; DOMINANT GENE; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION PROFILING; GENE MUTATION; GENETIC TRANSFECTION; GENETICS; GLIOBLASTOMA; HUMAN; HUMAN CELL; PATHOLOGY; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RADIATION DOSE; RADIATION EXPOSURE; RADIOSENSITIVITY; TUMOR GROWTH; VASCULAR ENDOTHELIUM;

APOPTOSIS; BRAIN NEOPLASMS; CELL MOVEMENT; COCULTURE TECHNIQUES; ENDOTHELIUM, VASCULAR; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION PROFILING; GENES, DOMINANT; GLIOBLASTOMA; HUMANS; PHENOTYPE; RADIATION TOLERANCE; TRANSFECTION; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 1242342063     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.11728     Document Type: Article

References (32)

1. Canman CE, Chen CY, Lee MH, Kastan MB. DNA damage responses: p53 induction, cell cycle perturbations, and apoptosis. Cold Spring Harb Symp Quant Biol 1994;59:277-86.
2. Sigal A, Rotter V. Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome. Cancer Res 2000;60: 6788-93.
3. Guimaraes DP, Hainaut P. TP53: a key gene in human cancer. Biochimie 2002;84:83-93.
4. Haas-Kogan DA, Kogan SS, Yount G, Hsu J, Haas M, Deen DF, Israel MA. p53 function influences the effect of fractionated radiotherapy on glioblastoma tumors. Int J Radiat Oncol Biol Phys 1999; 43:399-403.
5. Ceraline J, Deplanque G, Noel F, Natarajan-Ame S, Bergerat JP, Klein-Soyer C. Sensitivity to cisplatin treatment of human K1 thyroid carcinoma cell lines with altered p53 function. Cancer Chemother Pharmacol 2003;51:91-5.
6. Komarova EA, Diatchenko L, Rokhlin OW, Hill JE, Wang ZJ, Krivokrysenko VI, Feinstein E, Gudkov AV. Stress-induced secretion of growth inhibitors: a novel tumor suppressor function of p53. Oncogene 1998;17:1089-96.
7. Zhao R, Gish K, Murphy M, Yin Y, Notterman D, Hoffman WH, Tom E, Mack DH, Levine AJ. Analysis of p53-regulated gene expression patterns using oligonucleotide arrays. Genes Dev 2000; 14:981-93.
8. Kern A, Taubert H, Scheele J, Rudroff C, Mothes H, Kappler M, Bartel F, Richter KK. Association of p53 mutations, microvessel density and neoangiogenesis in pairs of colorectal cancers and corresponding liver metastases. Int J Oncol 2002;21:243-9.
9. Riedel F, Gotte K, Schwalb J, Schafer C, Hormann K. Vascular endothelial growth factor expression correlates with p53 mutation and angiogenesis in squamous cell carcinoma of the head and neck. Acta Otolaryngol 2000;120:105-11.
10. Uchida S, Shimada Y, Watanabe G, Tanaka H, Shibagaki I, Miyahara T, Ishigami S, Imamura M. In oesophageal squamous cell carcinoma vascular endothelial growth factor is associated with p53 mutation, advanced stage and poor prognosis. Br J Cancer 1998;77:1704-9.
11. Goodheart MJ, Vasef MA, Sood AK, Davis CS, Buller RE. Ovarian cancer p53 mutation is associated with tumor microvessel density. Gynecol Oncol 2002;86:85-90.
12. Strohmeyer D, Rossing C, Bauerfeind A, Kaufmann O, Schlechte H, Bartsch G, Loening S. Vascular endothelial growth factor and its correlation with angiogenesis and p53 expression in prostate cancer. Prostate 2000;45:216-24.
13. Khodarev NN, Yu J, Labay E, Darga T, Brown CK, Mauceri HJ, Yassari R, Gupta N, Weichselbaum RR. Tumour-endothelium interactions in co-culture: coordinated changes of gene expression profiles and phenotypic properties of endothelial cells. J Cell Sci 2003;116: 1013-22.
14. Gupta N, Vij R, Haas-Kogan DA, Israel MA, Deen DF, Morgan WF. Cytogenetic damage and the radiation-induced G1-phase checkpoint. Radiat Res 1996;145:289-98.
15. Pelizzari CA, Khodarev NN, Calvin DJ, Weichselbaum RR. Quantitative analysis of DNA array autoradiographs. Nucleic Acids Res 2000;28:4577-81.
16. Khodarev NN, Park J, Kataoka Y, Nodzenski E, Khorasani L, Hellman S, Roizman B, Weichselbaum RR, Pelizzari CA. Receiver operating characteristic analysis: a general tool for DNA array data filtration and performance estimation. Genomics 2003;81:202-9.
17. Kataoka Y, Murley JS, Khodarev NN, Weichselbaum RR, Grdina DJ. Activation of the nuclear transcription factor kappaB (NFkappaB) and differential gene expression in U87 glioma cells after exposure to the cytoprotector amifostine. Int J Radiat Oncol Biol Phys 2002;53: 180-9.
18. Gorski DH, Beckett MA, Jaskowiak NT, Calvin DP, Mauceri HJ, Salloum RM, Seetharam S, Koons A, Hari DM, Kufe DW, Weichselbaum RR. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res 1999;59:3374-8.
19. Fulci G, Ishii N, Maurici D, Gernert KM, Hainaut P, Kaur B, Van Meir EG. Initiation of human astrocytoma by clonal evolution of cells with progressive loss of p53 functions in a patient with a 283H TP53 germ-line mutation: evidence for a precursor lesion. Cancer Res 2002;62:2897-905.
20. Gaudet F, Hodgson JG, Eden A, Jackson-Grusby L, Dausman J, Gray JW, Leonhardt H, Jaenisch R. Induction of tumors in mice by genomic hypomethylation. Science 2003;300:489-92.
21. Duensing S, Munger K. The human papillomavirus type 16 E6 and E7 oncoproteins independently induce numerical and structural chromosome instability. Cancer Res 2002;62:7075-82.
22. Rizk NP, Chang MY, El Kouri C, Seth P, Kaiser LR, Albelda SM, Amin KM. The evaluation of adenoviral p53-mediated bystander effect in gene therapy of cancer. Cancer Gene Ther 1999;6:291-301.
23. Nishizaki M, Fujiwara T, Tanida T, Hizuta A, Nishimori H, Tokino T, Nakamura Y, Bouvet M, Roth JA, Tanaka N. Recombinant adenovirus expressing wild-type p53 is antiangiogenic: a proposed mechanism for bystander effect. Clin Cancer Res 1999;5:1015-23.
24. Harada H, Nakagawa K, Saito M, Kohno S, Nagato S, Furukawa K, Kumon Y, Hamada K, Ohnishi T. Introduction of wild-type p53 enhances thrombospondin-1 expression in human glioma cells. Cancer Lett 2003;191:109-19.
25. Mukhopadhyay D, Tsiokas L, Sukhatme VP. Wild-type p53 and v-Src exert opposing influences on human vascular endothelial growth factor gene expression. Cancer Res 1995;55:6161-5.
26. Kieser A, Weich HA, Brandner G, Marme D, Kolch W. Mutant p53 potentiates protein kinase C induction of vascular endothelial growth factor expression. Oncogene 1994;9:963-9.
27. Yu JL, Rak JW, Coomber BL, Hicklin DJ, Kerbel RS. Effect of p53 status on tumor response to antiangiogenic therapy. Science 2002; 295:1526-8.
28. Garcia-Barros M, Paris F, Cordon-Cardo C, Lyden D, Rafii S, Haimovitz-Friedman A, Fuks Z, Kolesnick R. Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science 2003;300:1155-9.
29. Nakase T, Fushiki S, Naus CC. Astrocytic gap junctions composed of connexin 43 reduce apoptotic neuronal damage in cerebral ischemia. Stroke 2003;34:1987-93.
30. Ozog MA, Siushansian R, Naus CC. Blocked gap junctional coupling increases glutamate-induced neurotoxicity in neuron-astrocyte cocultures. J Neuropathol Exp Neurol 2002;61:132-41.
31. Azzam EI, de Toledo SM, Little JB. Direct evidence for the participation of gap junction-mediated intercellular communication in the transmission of damage signals from alpha-particle irradiated to non-irradiated cells. Proc Natl Acad Sci USA 2001;98:473-8.
32. Hemann MT, Fridman JS, Zilfou JT, Hernando E, Paddison PJ, Cordon-Cardo C, Hannon GJ, Lowe SW. An epi-allelic series of p53 hypomorphs created by stable RNAi produces distinct tumor phenotypes in vivo. Nat Genet 2003;33:396-400.